| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE42152 | GENZYME | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
Dec, 2018
(5 years ago) | |
| US6987102 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(8 months ago) | |
| US7897590 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(8 months ago) | |
Mozobil is owned by Genzyme.
Mozobil contains Plerixafor.
Mozobil has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Mozobil are:
- USRE42152
- US6987102
- US7897590
Mozobil was authorised for market use on 15 December, 2008.
Mozobil is available in solution;subcutaneous dosage forms.
Mozobil can be used as use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma.
Drug patent challenges can be filed against Mozobil from 15 December, 2012.
The generics of Mozobil are possible to be released after 22 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 15, 2015 |
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2013 |
Drugs and Companies using PLERIXAFOR ingredient
NCE-1 date: 15 December, 2012
Market Authorisation Date: 15 December, 2008
Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with n...
Dosage: SOLUTION;SUBCUTANEOUS
MOZOBIL family patents
